Literature DB >> 11152496

Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

D K Wong1, D D Dudley, P B Dohrenwend, G M Lauer, R T Chung, D L Thomas, B D Walker.   

Abstract

Broadly directed hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTL) have been identified from liver-infiltrating lymphocytes but have been more difficult to assess in peripheral blood of infected persons. To enhance the detection of CTL from peripheral blood mononuclear cells (PBMC), we cocultured PBMC with autologous Epstein-Barr virus-transformed B-lymphoblastoid cell lines that had been infected with recombinant vaccinia virus constructs so that they expressed the entire translated polyprotein of HCV-H, a type 1a strain. These stimulated cells from HCV-infected as well as exposed seronegative persons were then cloned at limiting dilution and tested for HCV-specific CTL activity using a standard (51)Cr release assay. HCV-specific CTL were detected in PBMC from seven of nine persons with chronic hepatitis, including five of seven in whom CTL had previously been detected from liver biopsy specimens but not PBMC. In a single person with chronic HCV infection, CTL directed against as many as five different epitopes were detected in peripheral blood and were similar in specificity to those detected in liver tissue. This technique was used to evaluate eight subjects identified to be at high risk for HCV exposure due to continued injection drug abuse; no evidence of CTL in PBMC was found. We conclude that CTL can be detected in PBMC from the majority of persons with chronic HCV infection but are present at lower levels or absent in exposed but persistently seronegative persons. The high degree of concordance of HCV epitopes identified from liver and PBMC suggests that this strategy is a reasonable alternative to liver biopsy for characterizing the CTL response to HCV in chronically infected persons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152496      PMCID: PMC114029          DOI: 10.1128/JVI.75.3.1229-1235.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  HLA B44-restricted cytotoxic T lymphocyte responses to the peptides of HCV nucleoprotein residues 81-100 in patients with chronic hepatitis C.

Authors:  H Kita; T Moriyama; T Kaneko; H Okamoto; K Hiroishi; S Ohnishi; M Imawari
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

2.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

3.  HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.

Authors:  M J Koziel; D Dudley; N Afdhal; A Grakoui; C M Rice; Q L Choo; M Houghton; B D Walker
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  A minimal and optimal cytotoxic T cell epitope within hepatitis C virus nucleoprotein.

Authors:  H Kita; K Hiroishi; T Moriyama; H Okamoto; T Kaneko; S Ohnishi; Y Yazaki; M Imawari
Journal:  J Gen Virol       Date:  1995-12       Impact factor: 3.891

5.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

6.  Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Authors:  K Kurokohchi; T Akatsuka; C D Pendleton; A Takamizawa; M Nishioka; M Battegay; S M Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein.

Authors:  T Kaneko; I Nakamura; H Kita; K Hiroishi; T Moriyama; M Imawari
Journal:  J Gen Virol       Date:  1996-06       Impact factor: 3.891

8.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

Authors:  B Rehermann; K M Chang; J McHutchinson; R Kokka; M Houghton; C M Rice; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules.

Authors:  M Battegay; J Fikes; A M Di Bisceglie; P A Wentworth; A Sette; E Celis; W M Ching; A Grakoui; C M Rice; K Kurokohchi
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 10.  Correlates of hepatitis C virus infections among injection drug users.

Authors:  D L Thomas; D Vlahov; L Solomon; S Cohn; E Taylor; R Garfein; K E Nelson
Journal:  Medicine (Baltimore)       Date:  1995-07       Impact factor: 1.889

View more
  27 in total

1.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

2.  CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Shelly J Robertson; Simone Schimmer; Ronald J Messer; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.

Authors:  J Satoi; K Murata; M Lechmann; E Manickan; Z Zhang; H Wedemeyer; B Rehermann; T J Liang
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Authors:  Supriya Munshaw; Justin R Bailey; Lin Liu; William O Osburn; Kelly P Burke; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

5.  Functional measurement of hepatitis C virus core-specific CD8(+) T-cell responses in the livers or peripheral blood of patients by using autologous peripheral blood mononuclear cells as targets or stimulators.

Authors:  S H Fang; B L Chiang; M H Wu; H Iba; M Y Lai; P M Yang; D S Chen; L H Hwang
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 6.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

7.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 8.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load.

Authors:  Jing You; Lin Zhuang; Yi-Feng Zhang; Hong-Ying Chen; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Teerha Piratvisuth; Edward McNeil; Lan Yu; Bao-Zhang Tang; Jun-Hua Huang
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

10.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Authors:  Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.